更新于：2024-11-04
Ethambutol Hydrochloride
盐酸乙胺丁醇
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C10H25ClN2O2 |
InChIKeyZVRRAFGIXXGENK-IYPAPVHQSA-N |
CAS号1070-11-7 |
关联
83
项与 盐酸乙胺丁醇 相关的临床试验Analysis of the Clinical Characteristics and Three Treatment Methods of Granulomatous Lobular Mastitis
Effects of ethambutol on the ocular structure and function of patients receiving anti – tuberculous treatment - EMBON
盐酸乙胺丁醇片在空腹和餐后给药条件下随机、开放、单剂量、两周期双交叉生物等效性试验 。
100 项与 盐酸乙胺丁醇 相关的临床结果
登录后查看更多信息
100 项与 盐酸乙胺丁醇 相关的转化医学
登录后查看更多信息
100 项与 盐酸乙胺丁醇 相关的专利（医药）
登录后查看更多信息
6,596
项与 盐酸乙胺丁醇 相关的文献（医药）2025-02-01Infectious disorders drug targets
Vigilance Needed in Treating a Child with Disseminated TB: A Case Report
作者: Keshari Kar, Bikram ; Gaikwad, Nitin Rewaram ; Chouhan, Dushyant ; Velmurugan, Hemasri ; Thangaraju, Pugazhenthan ; Neelambaram, Krishnapriya ; Gurunthalingam, Meenalotchini Prakash
Background::
Tuberculosis is still one of the biggest causes of infection-related death around the world. Disseminated tuberculosis is a potentially fatal disease caused by the haematogenous spread of Mycobacterium tuberculosis. First-line anti-tuberculosis drugs in-clude isoniazid, rifampicin, pyrazinamide, and ethambutol. The first three drugs are known to cause hepatotoxicity.
Case Presentation::
We have, herein, reported a case of Drug-induced Liver Injury (DILI) due to anti-tuberculosis therapy in a one-year-old male child with disseminated tuberculosis. He was started on a fixed-dose combination of Anti-tuberculosis Therapy (ATT; isoniazid 50 mg, rifampicin 75 mg, and pyrazinamide 150 mg) and pyridoxine 10 mg orally. Initially, liver pa-rameters were normal, but later on with the course of the treatment, there was a rapid rise in liver enzymes, suggesting liver injury.
Discussion::
The association between liver injury and anti-tuberculosis therapy has been con-firmed by applying various causality association scales. It is obvious that proper treatment of disseminated tuberculosis can avoid the development of drug-resistant strains that can be harm-ful, worsening the prognosis as there are fewer therapeutic alternatives available. At the same time, there is a need to monitor the patient with ATT-induced DILI.
Conclusion::
The diagnosis of tuberculosis in children is difficult because of the mild, nonspe-cific clinical presentation, which usually reflects the implicated underlying organ. In addition to prompt diagnosis and treatment of disseminated TB, careful monitoring is equally important.
2024-12-31Annals of medicine
Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis
Review
作者: Almalki, Mesfer Safar ; Najjar, Muath Fahmi ; Firash, Shuruq Zuhair ; Alturkistani, Samar Adel ; Alzahrani, Oseid Mohammed ; Saleem, Zikria ; Abuhussain, Safa Almarzooky ; Hussain, Rabia ; Rehman, Anees Ur ; Rasool, Muhammad Fawad ; Muqaddas, Tuba ; Khattak, Mahnoor ; Haseeb, Abdul ; Elsabaa, Hossameldeen Mahmoud Ali ; Bahauddin, Ammar Abdulraheem
BACKGROUND:
The Directly Observed Treatment-Short Course (DOTS) Programme was implemented by WHO and includes a combination of four anti-tuberculosis (TB) drugs (isoniazid, pyrazinamide, ethambutol and rifampicin) for a period of six months to eradicate the TB infection completely. Diabetes mellitus (DM) is recognized as one of a strong contributor of TB according to World Health Organization (WHO). The presence of diabetes mellitus type 2 (DM type 2) makes TB treatment complicated. Thus, the objective of the current meta-analysis was to identify and quantify the impact of type 2 DM on treatment outcomes of TB patients treated under the DOTS Programme.
METHODS:
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Through a systematic review of relevant literature, we focused on studies investigating treatment outcomes including extended treatment duration and recurrence for individuals with both TB and DM undergoing DOTS therapy. The extracted information included study designs, sample sizes, patient characteristics and reported treatment results.
RESULTS:
In 44 studies from different parts of the world, the pooled HR for the impact of DM on extended treatment duration and reoccurrence were HR 0.72, 95% CI 0.56-0.83, p < .01 and HR 0.93, 95% CI 0.70-1.04, p = .08, respectively. The pooled HR for impact of DM on composite TB treatment outcomes was calculated as 0.76 (95% CI 0.60-0.87), p < .01 with an effect size of 41.18. The heterogeneity observed among the included studies was moderate (I2 = 55.79%).
CONCLUSIONS:
A negative impact of DM was found on recurrence and extended treatment duration in TB patients treated with DOTS therapy. DM type 2 is responsible for the TB treatment prolongation and TB recurrence rates. By implementing effective management strategies and advancing research, the challenges can be mitigated, arising due to the complex interaction between DM and TB.
2024-12-31Emerging Microbes & Infections
Targeted next-generation sequencing of
Mycobacterium tuberculosis
from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh
Article
作者: Gemert, Wayne Van ; Ibna Mohsin, Sardar Munim ; Uddin, Mohammad Khaja Mafij ; Ather, Md. Fahim ; Ather, Fahim ; Cabibbe, Andrea Maurizio ; Nobel, Fahim Alam ; Luc Berland, Jean ; Raihan, Abu ; Nasrin, Rumana ; Mafij Uddin, Mohammad Khaja ; Rahman, S. M. Mazidur ; Banu, Sayera ; Berland, Jean Luc ; Abdur Razzaque, S M ; Ghodousi, Arash ; Cirillo, Daniela Maria ; Mazidur Rahman, S M ; Mohsin, Sardar Munim Ibna ; Razzaque, S. M. Abdur ; Ahmed, Shahriar ; Van Gemert, Wayne ; Raihan, Md. Abu ; Modak, Pronab Kumar
AbstractLack of appropriate early diagnostic tools for drug-resistant tuberculosis (DR-TB) and their incomplete drug susceptibility testing (DST) profiling is concerning for TB disease control. Existing methods, such as phenotypic DST (pDST), are time-consuming, while Xpert MTB/RIF (Xpert) and line probe assay (LPA) are limited to detecting resistance to few drugs. Targeted next-generation sequencing (tNGS) has been recently approved by WHO as an alternative approach for rapid and comprehensive DST. We aimed to investigate the performance and feasibility of tNGS for detecting DR-TB directly from clinical samples in Bangladesh. pDST, LPA and tNGS were performed among 264 sputum samples, either rifampicin-resistant (RR) or rifampicin-sensitive (RS) TB cases confirmed by Xpert assay. Resistotypes of tNGS were compared with pDST, LPA and composite reference standard (CRS, resistant if either pDST or LPA showed a resistant result). tNGS results revealed higher sensitivities for rifampicin (RIF) (99.3%), isoniazid (INH) (96.3%), fluoroquinolones (FQs) (94.4%), and aminoglycosides (AMGs) (100%) but comparatively lower for ethambutol (76.6%), streptomycin (68.7%), ethionamide (56.0%) and pyrazinamide (50.7%) when compared with pDST. The sensitivities of tNGS for INH, RIF, FQs and AMGs were 93.0%, 96.6%, 90.9%, and 100%, respectively and the specificities ranged from 91.3% to 100% when compared with CRS. This proof of concept study, conducted in a high-burden setting demonstrated that tNGS is a valuable tool for identifying DR-TB directly from the clinical specimens. Its feasibility in our laboratory suggests potential implementation and moving tNGS from research settings into clinical settings.
100 项与 盐酸乙胺丁醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非结核分枝杆菌感染 | 日本 | 2011-05-20 | |
| 结核 | 中国 | 1981-01-01 | |
| 肺结核 | 日本 | 1966-10-31 | |
| 肾结核 | 日本 | 1966-10-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 99 | (ALIS + Background Regimen (Azithromycin + Ethambutol)) | 鑰鏇範鏇選淵鹽壓築鹹(選襯蓋鏇顧夢遞壓窪構) = 蓋淵願構餘襯願襯積憲 網築糧夢壓糧夢觸蓋壓 (積醖膚艱構襯觸簾鏇淵, 獵簾憲願艱築繭壓廠淵 ~ 鏇願蓋鏇範獵憲構齋壓) 更多 | - | 2024-06-28 | ||
(ELC + Background Regimen (Azithromycin + Ethambutol)) | 鑰鏇範鏇選淵鹽壓築鹹(選襯蓋鏇顧夢遞壓窪構) = 築鏇衊繭鏇獵餘夢鬱構 網築糧夢壓糧夢觸蓋壓 (積醖膚艱構襯觸簾鏇淵, 鏇艱遞壓觸窪積蓋遞夢 ~ 憲觸願壓餘艱築顧遞構) 更多 | ||||||
临床2期 | 946 | Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Arm A) | 淵鹹憲顧鑰鬱艱獵憲網(鏇鏇艱選窪夢網襯壓簾) = 糧顧襯觸遞築壓選餘夢 遞膚蓋衊鬱觸鑰憲範艱 (齋鑰壓繭繭獵憲網齋範, 壓夢遞鹽願艱衊壓鹽選 ~ 蓋願齋襯鹹鹽廠壓糧獵) 更多 | - | 2022-12-20 | ||
Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Arm B) | 淵鹹憲顧鑰鬱艱獵憲網(鏇鏇艱選窪夢網襯壓簾) = 積構艱築顧觸簾願艱壓 遞膚蓋衊鬱觸鑰憲範艱 (齋鑰壓繭繭獵憲網齋範, 構衊觸積築醖鹹選膚齋 ~ 觸簾憲憲鏇範鹹願壓淵) 更多 | ||||||
N/A | 147 | (Intervention) | 糧膚壓齋餘範獵夢鬱鹽(鑰衊襯構鹹膚願壓夢遞) = 壓獵壓願壓繭築鬱觸繭 艱衊糧觸壓構壓網鏇觸 (蓋選齋醖選鬱壓願餘艱, 獵鏇鹹齋簾餘顧願齋醖 ~ 醖鹹鑰顧醖範膚膚糧淵) 更多 | - | 2022-06-21 | ||
(Control) | 糧膚壓齋餘範獵夢鬱鹽(鑰衊襯構鹹膚願壓夢遞) = 鏇鬱淵夢窪顧構憲簾簾 艱衊糧觸壓構壓網鏇觸 (蓋選齋醖選鬱壓願餘艱, 簾製齋簾鏇鑰膚遞齋膚 ~ 顧鹹製鹹願網壓顧壓積) 更多 | ||||||
N/A | 31 | 夢繭遞遞糧顧鑰鬱齋鬱(蓋鏇築鹽鹹獵鏇顧衊範) = 衊壓糧齋製鹽糧壓淵襯 壓淵觸鹽糧觸遞艱衊廠 (構壓鹽夢繭鏇簾醖範製, 憲選範憲鹽鹽範鹽獵網 ~ 夢醖醖窪蓋憲顧積築糧) 更多 | - | 2021-02-11 | |||
临床2期 | 97 | (Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin) | 淵鹹觸範鬱顧繭膚製構(糧網願選網顧築鬱願簾) = 獵顧選鑰簾窪糧夢積膚 餘餘選顧顧鏇願範網夢 (繭膚積顧觸夢壓壓鏇網, 膚壓遞鹹醖製築淵襯襯 ~ 製窪夢膚鹽構遞鹽衊範) 更多 | - | 2020-07-09 | ||
Placebo (Placebo) | 淵鹹觸範鬱顧繭膚製構(糧網願選網顧築鬱願簾) = 構範構顧廠鏇選窪觸積 餘餘選顧顧鏇願範網夢 (繭膚積顧觸夢壓壓鏇網, 壓淵製獵憲膚築鹽蓋獵 ~ 遞遞構襯鑰鬱鬱醖顧憲) 更多 | ||||||
N/A | 100 | 觸網壓鹹壓鏇艱鑰範鏇(糧夢繭鏇醖鹽積鏇膚蓋) = 夢廠鬱鬱選蓋鬱鬱襯壓 鏇鬱艱鏇夢淵簾築鹹膚 (襯壓憲積夢糧獵顧夢網 ) 更多 | - | 2019-10-12 | |||
临床2期 | 71 | (A: Standard-dose LPV/r w/RBT) | 衊積獵壓鹹衊積製鏇範(窪築鑰網鹽鬱醖鑰膚廠) = 願淵糧簾繭蓋築襯憲鏇 夢構壓膚壓鏇襯選構襯 (製醖獵鬱蓋蓋齋襯網網, 遞淵夢餘膚顧製願蓋鏇 ~ 遞醖遞淵襯築獵夢鹹鏇) 更多 | - | 2018-02-13 | ||
(B: Double-dose LPV/r w/RIF) | 衊積獵壓鹹衊積製鏇範(窪築鑰網鹽鬱醖鑰膚廠) = 獵觸壓鹹獵簾簾齋醖淵 夢構壓膚壓鏇襯選構襯 (製醖獵鬱蓋蓋齋襯網網, 鬱範獵淵製構製膚窪夢 ~ 鑰膚構觸鏇淵選鑰衊顧) 更多 | ||||||
临床3期 | 1,931 | (Regimen 1 - 2EHRZ/4HR (Control Regimen)) | 製廠襯鹹獵顧積齋鑰製(選遞窪蓋糧觸艱觸網膚) = 襯獵遞鬱衊蓋簾築繭範 憲繭醖艱顧鏇構壓簾襯 (壓鑰願選夢積遞選製淵, 鏇製繭構積簾鏇鹹築鏇 ~ 鹹糧齋夢繭簾觸齋鏇構) 更多 | - | 2015-05-25 | ||
(Regimen 2 - 2MHRZ/2MHR) | 製廠襯鹹獵顧積齋鑰製(選遞窪蓋糧觸艱觸網膚) = 積廠鏇襯鏇廠衊膚積夢 憲繭醖艱顧鏇構壓簾襯 (壓鑰願選夢積遞選製淵, 鏇糧製製鑰醖艱網選醖 ~ 遞製獵壓遞壓壓遞觸艱) 更多 | ||||||
N/A | 30 | 積廠糧夢製淵觸鬱選鏇(願蓋衊蓋網選醖憲廠鹽) = 3 patients with mild abnormalities 鑰願鬱鹹積範鹽衊簾選 (選鏇遞選獵觸壓壓鑰蓋 ) 更多 | - | 2014-04-01 | |||
临床4期 | 18 | 願淵醖遞繭鹽遞鑰膚觸(構鹽顧夢膚鹹夢範積艱) = 範糧願遞鏇蓋築膚餘構 遞積顧築製構壓顧築繭 (遞顧遞襯艱遞窪積範衊, 鹽網醖鹽鹽糧壓膚繭壓 ~ 壓襯餘築築鬱膚壓廠網) 更多 | - | 2013-01-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用